Novavax sees weak Covid vaccine sales
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
Hosted on MSN22h
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call TranscriptThis strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
Health-care companies slipped as vaccine makers remained under pressure. Shares of Novavax plunged by 8%, compounding losses in the wake of the vaccine developer's earnings report. Rival Moderna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback